GlassScriptPhysician profile
James A Miller
NPI 1841297256
$6,488.43
in general payments reported to CMS, 2019-2025
46 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $653 · 2021: $1,126 · 2022: $1,284 · 2023: $918 · 2024: $1,200 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $923.50 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $892.05 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $693.31 | 2021-2025 | |
| Exact Sciences Corporation | $346.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $322.85 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $264.14 | 2019-2022 | |
| Antares Pharma, INC. | $194.67 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $190.09 | 2019-2024 | Xarelto |
| Amgen INC. | $179.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.73 | 2021-2023 | |
| Glaxosmithkline, LLC. | $157.29 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.78 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $138.27 | 2023-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.74 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $119.10 | 2022-2025 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.